Adjuvant endocrine therapies such as tamoxifen, a selective estrogen receptor modulator, and aromatase inhibitors (AIs) such as anastrozole, letrozole, or exemestane are often administered as maintenance therapy to individuals with breast cancer who have completed curative treatment [3]. The gene discussed is CYP19A1; the disease is breast cancer.